Medicare is prohibited from covering weight loss medications, but recent data showing potential positive health effects could increase pressure on US policymakers to change the law. The cost of removing the prohibition and the potential savings in overall health spending will be important information for Congress to consider before passing any legislation, according to Bill Hoagland, senior vice president of the Bipartisan Policy Center. Hoagland joins Bloomberg Intelligence analysts Duane Wright and Michael Shah on this episode of the Votes and Verdicts podcast to discuss how legislative revenue and spending projections are developed, why they’re important and how it could influence whether Medicare will begin covering weight-loss drugs.

See omnystudio.com/listener for privacy information.